Jacqueline French
Neurology · New York, NYNPI 1689606832
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $202,542 of the $236,892 with a category attached, or 85.5%. It is spread thinly across 28 manufacturers, the largest accounting for just 14.0%. Reporting peaked in 2019 at $78,481 and has fallen 59.3% since, to $31,927 in 2025. Among neurology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 211 payments — averaging $1122.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka Pharmaceutical Development & Commercialization, Inc.$33K
- Biogen$32K
- UCB SA$30K
- Eisai Inc.$29K
- Neurocrine Biosciences, Inc.$26K
- UCB, Inc.$15K
- plus $72K from 22 others
Across 6 payments — averaging $590.83 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Supernus Pharmaceuticals, Inc.$2K
- UCB, Inc.$820
- Medtronic$700
What the payments were for
- Consulting fees$202,54285%
- Speaking & faculty fees$12,5255%
- Travel & lodging$20,1248%
- Food & beverage$1,7001%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 27 | $33,170 |
| Biogen | 28 | $31,875 |
| UCB SA | 18 | $30,000 |
| Eisai Inc. | 7 | $29,025 |
| Neurocrine Biosciences, Inc. | 26 | $25,612 |
| UCB, Inc. | 12 | $15,098 |
| Jazz Pharmaceuticals Inc. | 22 | $14,491 |
| Sage Therapeutics, LLC | 11 | $7,601 |
| Livanova USA, Inc. | 8 | $6,780 |
| Immedica Pharma US, Inc. | 3 | $6,625 |
| H. Lundbeck A S | 3 | $6,613 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $6,241 |
| Greenwich Biosciences, Inc. | 2 | $4,000 |
| SK Life Science, Inc. | 3 | $3,450 |
| Supernus Pharmaceuticals, Inc. | 7 | $3,275 |
| UCB Biosciences Inc. | 9 | $2,400 |
| Biomarin Pharmaceutical Inc. | 1 | $2,250 |
| Genentech, Inc. | 1 | $2,100 |
| Eisai CO., LTD. | 1 | $2,069 |
| Pfizer | 1 | $1,000 |
| Neuropace, Inc. | 2 | $906 |
| Alkermes, Inc. | 1 | $650 |
| Merck | 1 | $500 |
| GW Research Limited | 1 | $500 |
| Shire North American Group Inc | 1 | $450 |
| Lundbeck LLC | 1 | $100 |
| Ceribell, Inc. | 1 | $88 |
| Neurelis, Inc. | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Epidiolex$14,396
- ZTALMY$5,000
- VNS THERAPY SENTIVA MODEL 1000 GENERATOR$4,725
- Fycompa$2,294
- TYSABRI$2,206
- CellCept$2,100
- Enspryng$2,100
- VNS - Sentiva$2,000
- ADUHELM$1,839
- Vimpat$1,100
- RNS Neurostimulator Kit$906
- XCOPRI$600
- Briviact$125
How this compares
$236,892 in reported general payments places this provider in the 95th percentile of 1,623 neurology providers in New York.
Other neurology in New York
- Stephen KriegerNew York$1.1M
- Sheng-Han KuoNew York$657K
- Timothy VartanianNew York$468K
- Steven WolfNew York$428K
- David DodickNew York$426K
- David SimpsonNew York$403K
- Fred LublinNew York$383K
- Alexander ShtilbansNew York$374K
- Andrew LassmanNew York$359K
- Brian ApatoffNew York$295K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.